Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapy
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Open-Angle Glaucoma
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Trial Timeline
Dec 1, 2014 → Dec 1, 2015
NCT ID
NCT02325518About Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapy
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapy is a approved stage product being developed by Novartis for Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02325518. Target conditions include Open-Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02325518 | Approved | Completed |
Competing Products
20 competing products in Open-Angle Glaucoma